Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO Sells $31,484.53 in Stock

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction dated Friday, February 7th. The stock was sold at an average price of $3.41, for a total value of $31,484.53. Following the sale, the chief executive officer now owns 3,785,350 shares of the company’s stock, valued at approximately $12,908,043.50. This represents a 0.24 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.

Checkpoint Therapeutics Stock Up 3.3 %

CKPT stock opened at $3.46 on Friday. Checkpoint Therapeutics, Inc. has a 52-week low of $1.38 and a 52-week high of $4.50. The company has a market capitalization of $168.95 million, a PE ratio of -1.88 and a beta of 1.36. The stock’s 50 day moving average is $3.36 and its two-hundred day moving average is $3.00.

Checkpoint Therapeutics (NASDAQ:CKPT) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08). As a group, sell-side analysts anticipate that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in shares of Checkpoint Therapeutics by 4.1% in the fourth quarter. Geode Capital Management LLC now owns 445,111 shares of the company’s stock valued at $1,425,000 after buying an additional 17,460 shares during the period. HB Wealth Management LLC raised its position in Checkpoint Therapeutics by 96.9% during the fourth quarter. HB Wealth Management LLC now owns 153,560 shares of the company’s stock valued at $513,000 after buying an additional 75,560 shares during the period. PVG Asset Management Corp raised its position in Checkpoint Therapeutics by 9.2% during the third quarter. PVG Asset Management Corp now owns 149,870 shares of the company’s stock valued at $336,000 after buying an additional 12,676 shares during the period. Wealth Enhancement Advisory Services LLC raised its position in Checkpoint Therapeutics by 160.0% during the third quarter. Wealth Enhancement Advisory Services LLC now owns 130,000 shares of the company’s stock valued at $291,000 after buying an additional 80,000 shares during the period. Finally, State Street Corp grew its stake in Checkpoint Therapeutics by 32.2% in the third quarter. State Street Corp now owns 94,424 shares of the company’s stock valued at $212,000 after purchasing an additional 23,000 shares in the last quarter. Institutional investors and hedge funds own 22.00% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on CKPT. D. Boral Capital began coverage on Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 price objective for the company. HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. Finally, Lake Street Capital raised their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the stock a “buy” rating in a research note on Monday, December 16th.

About Checkpoint Therapeutics

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.